[1]董心月,张伶俐,邵 蓉.英国价值定价理念与药品补偿制度的衔接及启示[J].卫生经济研究,2018,(10):54-57.
　DONG Xin-yue,ZHANG Ling-li,SHAO Rong.The Connection and Enlightenment of British Value Pricing Concept and Drug Compensation System[J].Journal Press of Health Economics Research,2018,(10):54-57.
点击复制

英国价值定价理念与药品补偿制度的衔接及启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2018年10期
页码:
54-57
栏目:
他山之石
出版日期:
2018-10-05

文章信息/Info

Title:
The Connection and Enlightenment of British Value Pricing Concept and Drug Compensation System
作者:
董心月1; 张伶俐2; 邵 蓉1
1.中国药科大学国家药物政策与医药产业经济研究中心，江苏 南京211198
2.南京总医院，江苏 南京 210002
Author(s):
DONG Xin-yue;  ZHANG Ling-li;  SHAO Rong
National Pharmaceutical Policy and Pharmaceutical Industry Economic Research Center, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
价值定价理念; 药品补偿目录; 药物警戒体系; 药物经济学; 临床价值; 英国
Keywords:
value pricing concept;  drug compensation policy;  pharmacovigilance system;  pharmacoeconomics;  UK
分类号:
R951
文献标志码:
A
摘要:
通过对英国价值定价理念及其与药品补偿制度衔接模式的阐述，深入分析价值定价理念的实施背景及在药品补偿制度中的具体应用，并结合国情，提出我国应建立药物经济学评价的官方体系、完善药物警戒系统、实施药品再评价等政策建议。
Abstract:
Through the elaboration of the UK value pricing concept and its connection model with the drug compensation system, the paper analyzed the implementation background of the value pricing concept and the specific application in the drug compensation system, suggested that China should put forward the official system of drug economics evaluation, improve the drug warning system and implement drug re-evaluation policy.

参考文献/References:

[1] 邵蓉, 葛其南, 谢金平. 典型地区医保特药谈判制度研究及对医保药品目录谈判的启示[J]. 广东药科大学学报, 2017, 33(4): 518-521.
[2] 申静静. 药品价格形成机制与医保支付标准的研究[D]. 北京: 首都经济贸易大学, 2017.
[3] 董朝晖. 对于医保支付标准形成机制的展望[J]. 中国医疗保险, 2015(7): 21-23，29.
[4] 王青宇, 高岩, 刘伟, 等. 我国医保药品支付价格政策改革探讨[J]. 中国药房, 2015, 26(21): 2881-2884.
[5] DH. Heads of Agreement for the 2014 Pharmaceutical Price Regulation Scheme [OB/OL]. （2013-11-06）[2018-03-20].https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/255252/pprs_heads_of_agreement_2014.pdf .
[6] Livio Garattini, Dante Cornago. Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis[J]. HealthPolicy, 2007(82): 330-339.
[7] David J Webb, Andrew Walker. Value-based pricing of drugs in the UK[J]. The Lancet, 2007, 369(9571): 1415-1416.
[8] NICE. Value based assessment methods consultation document[OB/OL]. [2018-02-21].https://www. nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-technology-appraisals/VBA-TA-Methods-Guide-for-Consultation.pdf.
[9] Darius Lakdawalla, Anup Malani, Julian Reif. The insurance value of medical innovation [J]. Journal of Public Economics, 2017(145): 94-102.

更新日期/Last Update: 2018-09-29